Xcout IntelBeyondSpring, Inc. competitors & alternatives
The 12 closest competitors and alternatives to BeyondSpring, Inc. among biotech companies — ranked by similarity to what BeyondSpring, Inc. actually does, not by market-cap band.
Subscribe to see BeyondSpring, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BeyondSpring, Inc.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
BeyondSpring, Inc. at a glance
BeyondSpring, Inc. is a biotech company headquartered in Florham Park, United States. It is publicly listed (BYSI) with a market capitalisation of $30.8M. Xcout tracks 14 named people at BeyondSpring, Inc., including Min Qiu (Chief Executive Officer).
BeyondSpring, Inc. leadership
- Min QiuChief Executive Officer
- Na LiChief Financial Officer
- June LuChief Scientific Officer
- Lan HuangCo-Founder & Chair of the Board
- John MaoSenior Vice President of Development
- Joy JiaVice President of Finance
8 more named people on record for BeyondSpring, Inc., with roles, board committees and tenure — see the full roster →
BeyondSpring, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $15.3M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 BeyondSpring, Inc. competitors
Ranked by semantic similarity — how close each company is to BeyondSpring, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs targeting key pathways. Headquartered in New York and Palo Alto with additional offices in Asia, the company was founded in 2010.
Similar biotech company
Beyond Bio is a biotechnology company that researches and develops novel therapeutics for various oncological and neurological conditions, including pancreatic cancer, colorectal cancer, glioblastoma, blood cancer, lung cancer, and Alzheimer's disease. The company also develops proprietary drug delivery technologies to support its therapeutic pipeline.
Similar biotech company
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Biotechnology
Bakx Therapeutics, Inc. is a private biotechnology company founded in 2020 and based in New York, United States. The company specializes in pre-clinical oncology drug pipelines and novel therapeutics discovery.
Similar biotech company
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Biotechnology
Phosplatin Therapeutics Inc. is a New York-based, privately held clinical-stage pharmaceutical company dedicated to advancing oncology therapeutics through an exclusive global license to phosphaplatins.
Biotechnology
SpringWorks Therapeutics, Inc. is a healthcare company focused on targeted oncology. It is located at 100 Washington Blvd, Stamford, Connecticut.
Similar biotech company
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Similar biotech company
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Biotechnology
Novita Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in New York, New York, dedicated to developing first-in-class drugs to prevent and treat cancer.
Similar biotech company
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Similar biotech company
Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United States. The company boasts a comprehensive pipeline of drug candidates. In oncology, its key developments include: MSB2311, a humanized PD-L1 monoclonal antibody, currently in Phase Ib/IIa trials for various solid tumors, particularly those with high tumor mutational burden (TMB-H). TST001, a humanized claudin 18.2 monoclonal antibody undergoing Phase II clinical development for solid tumors, such as gastric cancer. TST005, a bifunctional PD-L1/TGF-ß antibody in Phase Ia clinical trials for solid tumors, including certain types of lung cancer. TST010, an antibody designed to target regulatory T cells, aiming to bolster T cell-mediated anti-tumor activity. TST003, an antibody addressing a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells exhibiting a mesenchymal phenotype. TST006, a bispecific antibody targeting both claudin 18.2 and PD-L1. TST008, a trifunctional antibody that combines a MASP2 antibody with a truncated transmembrane activator and CAML interactor protein. MSB0254, a humanized VEGFR-2 monoclonal antibody also in Phase Ib/IIa clinical studies for solid tumors. Beyond cancer, Transcenta is advancing: TST002 (Blosozumab), a humanized sclerostin monoclonal antibody for the treatment of osteoporosis. TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) monoclonal antibody intended for IgA kidney diseases. The company has forged collaboration agreements with prominent organizations, including Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. Founded in 2010 as MabSpace International Limited, the entity adopted the name Transcenta Holding Limited in June 2019. Its corporate headquarters are located in Suzhou, People's Republic of China.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BeyondSpring, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BeyondSpring, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →